SUPERNUS PHARMACEUTICALS INC (SUPN) Fundamental Analysis & Valuation
NASDAQ:SUPN • US8684591089
Current stock price
50.96 USD
+0.42 (+0.83%)
At close:
50.96 USD
0 (0%)
After Hours:
This SUPN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SUPN Profitability Analysis
1.1 Basic Checks
- SUPN had positive earnings in the past year.
- SUPN had a positive operating cash flow in the past year.
- Of the past 5 years SUPN 4 years were profitable.
- SUPN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -2.65%, SUPN is in the better half of the industry, outperforming 74.48% of the companies in the same industry.
- SUPN has a better Return On Equity (-3.63%) than 77.60% of its industry peers.
- With a decent Return On Invested Capital value of 0.76%, SUPN is doing good in the industry, outperforming 78.13% of the companies in the same industry.
- SUPN had an Average Return On Invested Capital over the past 3 years of 2.78%. This is significantly below the industry average of 13.06%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.65% | ||
| ROE | -3.63% | ||
| ROIC | 0.76% |
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)2.78%
ROIC(5y)3.35%
1.3 Margins
- SUPN has a better Operating Margin (1.55%) than 78.13% of its industry peers.
- SUPN's Operating Margin has declined in the last couple of years.
- SUPN has a better Gross Margin (89.89%) than 91.67% of its industry peers.
- In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.55% | ||
| PM (TTM) | N/A | ||
| GM | 89.89% |
OM growth 3Y-36.8%
OM growth 5Y-45.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.12%
GM growth 5Y0%
2. SUPN Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
- SUPN has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, SUPN has more shares outstanding
- There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- SUPN has an Altman-Z score of 5.74. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
- SUPN has a Altman-Z score of 5.74. This is in the better half of the industry: SUPN outperforms 79.17% of its industry peers.
- There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.74 |
ROIC/WACC0.08
WACC9.24%
2.3 Liquidity
- SUPN has a Current Ratio of 1.90. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
- SUPN's Current ratio of 1.90 is on the low side compared to the rest of the industry. SUPN is outperformed by 63.54% of its industry peers.
- SUPN has a Quick Ratio of 1.66. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
- SUPN has a worse Quick ratio (1.66) than 60.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.9 | ||
| Quick Ratio | 1.66 |
3. SUPN Growth Analysis
3.1 Past
- SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.14%, which is quite good.
- SUPN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.21% yearly.
- SUPN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.63%.
- Measured over the past years, SUPN shows a small growth in Revenue. The Revenue has been growing by 6.68% on average per year.
EPS 1Y (TTM)8.14%
EPS 3Y45.76%
EPS 5Y6.21%
EPS Q2Q%12%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%
3.2 Future
- The Earnings Per Share is expected to grow by 17.52% on average over the next years. This is quite good.
- The Revenue is expected to grow by 14.29% on average over the next years. This is quite good.
EPS Next Y-38.5%
EPS Next 2Y23.69%
EPS Next 3Y18.42%
EPS Next 5Y17.52%
Revenue Next Year23.16%
Revenue Next 2Y20.6%
Revenue Next 3Y18.26%
Revenue Next 5Y14.29%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. SUPN Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 15.97 indicates a correct valuation of SUPN.
- Based on the Price/Earnings ratio, SUPN is valued cheaply inside the industry as 85.94% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 26.21. SUPN is valued slightly cheaper when compared to this.
- With a Price/Forward Earnings ratio of 25.98, SUPN can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, SUPN is valued a bit cheaper than 74.48% of the companies in the same industry.
- SUPN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.10.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.97 | ||
| Fwd PE | 25.98 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, SUPN is valued a bit cheaper than the industry average as 79.69% of the companies are valued more expensively.
- 76.56% of the companies in the same industry are more expensive than SUPN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 63.8 | ||
| EV/EBITDA | 23.57 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as SUPN's earnings are expected to grow with 18.42% in the coming years.
PEG (NY)N/A
PEG (5Y)2.57
EPS Next 2Y23.69%
EPS Next 3Y18.42%
5. SUPN Dividend Analysis
5.1 Amount
- SUPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SUPN Fundamentals: All Metrics, Ratios and Statistics
50.96
+0.42 (+0.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24 2026-02-24/amc
Earnings (Next)05-04 2026-05-04
Inst Owners103.58%
Inst Owner Change0%
Ins Owners4.32%
Ins Owner Change1.51%
Market Cap2.93B
Revenue(TTM)718.95M
Net Income(TTM)-38.55M
Analysts83.33
Price Target64.43 (26.43%)
Short Float %7.61%
Short Ratio5.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)105.02%
Min EPS beat(2)67.83%
Max EPS beat(2)142.22%
EPS beat(4)4
Avg EPS beat(4)78.33%
Min EPS beat(4)15.55%
Max EPS beat(4)142.22%
EPS beat(8)7
Avg EPS beat(8)76.31%
EPS beat(12)10
Avg EPS beat(12)66.61%
EPS beat(16)11
Avg EPS beat(16)43.29%
Revenue beat(2)2
Avg Revenue beat(2)5.83%
Min Revenue beat(2)5.28%
Max Revenue beat(2)6.37%
Revenue beat(4)3
Avg Revenue beat(4)4.06%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)6.37%
Revenue beat(8)6
Avg Revenue beat(8)5.39%
Revenue beat(12)9
Avg Revenue beat(12)4.44%
Revenue beat(16)11
Avg Revenue beat(16)2.87%
PT rev (1m)2.99%
PT rev (3m)2.99%
EPS NQ rev (1m)-16.57%
EPS NQ rev (3m)11.24%
EPS NY rev (1m)-46.67%
EPS NY rev (3m)-54.71%
Revenue NQ rev (1m)-1.01%
Revenue NQ rev (3m)0.41%
Revenue NY rev (1m)0.88%
Revenue NY rev (3m)-0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.97 | ||
| Fwd PE | 25.98 | ||
| P/S | 4.08 | ||
| P/FCF | 63.8 | ||
| P/OCF | 61.99 | ||
| P/B | 2.76 | ||
| P/tB | 7.99 | ||
| EV/EBITDA | 23.57 |
EPS(TTM)3.19
EY6.26%
EPS(NY)1.96
Fwd EY3.85%
FCF(TTM)0.8
FCFY1.57%
OCF(TTM)0.82
OCFY1.61%
SpS12.49
BVpS18.44
TBVpS6.38
PEG (NY)N/A
PEG (5Y)2.57
Graham Number36.38
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.65% | ||
| ROE | -3.63% | ||
| ROCE | 1% | ||
| ROIC | 0.76% | ||
| ROICexc | 1.05% | ||
| ROICexgc | 7.57% | ||
| OM | 1.55% | ||
| PM (TTM) | N/A | ||
| GM | 89.89% | ||
| FCFM | 6.4% |
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)2.78%
ROIC(5y)3.35%
ROICexc(3y)4.57%
ROICexc(5y)5.05%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.69%
ROCE(5y)4.7%
ROICexgc growth 3Y-30.81%
ROICexgc growth 5Y-24.6%
ROICexc growth 3Y-31.42%
ROICexc growth 5Y-41%
OM growth 3Y-36.8%
OM growth 5Y-45.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.12%
GM growth 5Y0%
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.46% | ||
| Cap/Sales | 0.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 46.07% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.9 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 5.74 |
F-Score5
WACC9.24%
ROIC/WACC0.08
Cap/Depr(3y)1%
Cap/Depr(5y)1.92%
Cap/Sales(3y)0.13%
Cap/Sales(5y)0.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.14%
EPS 3Y45.76%
EPS 5Y6.21%
EPS Q2Q%12%
EPS Next Y-38.5%
EPS Next 2Y23.69%
EPS Next 3Y18.42%
EPS Next 5Y17.52%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%
Revenue Next Year23.16%
Revenue Next 2Y20.6%
Revenue Next 3Y18.26%
Revenue Next 5Y14.29%
EBIT growth 1Y-87.66%
EBIT growth 3Y-35.2%
EBIT growth 5Y-41.44%
EBIT Next Year14.86%
EBIT Next 3Y40.14%
EBIT Next 5Y27.81%
FCF growth 1Y-73.14%
FCF growth 3Y-26.62%
FCF growth 5Y-19.37%
OCF growth 1Y-72.47%
OCF growth 3Y-26%
OCF growth 5Y-19.31%
SUPERNUS PHARMACEUTICALS INC / SUPN Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to SUPN.
What is the valuation status for SUPN stock?
ChartMill assigns a valuation rating of 4 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.
How profitable is SUPERNUS PHARMACEUTICALS INC (SUPN) stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for SUPN stock?
The Price/Earnings (PE) ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 15.97 and the Price/Book (PB) ratio is 2.76.
How financially healthy is SUPERNUS PHARMACEUTICALS INC?
The financial health rating of SUPERNUS PHARMACEUTICALS INC (SUPN) is 6 / 10.